与氨基糖化物相关的耳毒性药物遗传学:系统性审查
D Gaafar1,2,3, N Baxter2, N Cranswick1,2,3
1Infectious Diseases and Clinical Pharmacology Units, Department of General Medicine, Royal Children's Hospital, Parkville, Australia.
The Journal of antimicrobial chemotherapy
|April 17, 2024
概括
像MT-RNR1中的m.1555A>G这样的遗传变异与氨基甘油酸抗生素的耳毒性有很强的联系,导致听力损失. m.1494C>T变种也显示出相关性,尽管不那么一致.
科学领域:
- 药物遗传学 药物遗传学
- 基因组学就是基因组学.
- 耳毒性研究研究
背景情况:
- 氨基糖化物 (AGs) 对于治疗格拉姆阴性败血症至关重要,但有不可逆转的感觉神经听力损失 (SNHL) 的风险.
- 遗传因素与AG诱导的耳毒性有关.
- 了解这些遗传决定因素对于患者的安全至关重要.
结论:
- 在MT-RNR1中的m.1555A>G和m.1494C>T变异是AG诱导的SNHL的关键药物遗传决定因素.
- 这些变异与使用氨基糖类抗生素后发展SNHL的高风险有关.
- 研究质量有限 (2-4级证据),强调需要进一步研究.
相关概念视频
Estimation of k and VD of Aminoglycosides
335
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
335
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
354
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
354
Pharmacogenetics and Pharmacogenomics: Overview
253
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
253
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Drug Toxicity: Risk factors
229
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
229
Inhibitors of Bacterial Protein Synthesis
106
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
106


